261 related articles for article (PubMed ID: 33268528)
1. Cyclophosphamide and Vinorelbine Activate Stem-Like CD8
Falvo P; Orecchioni S; Hillje R; Raveane A; Mancuso P; Camisaschi C; Luzi L; Pelicci P; Bertolini F
Cancer Res; 2021 Feb; 81(3):685-697. PubMed ID: 33268528
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
4. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
5. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
6. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
7. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Plasmid IL12 Expands CD8
Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
12. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
Orecchioni S; Talarico G; Labanca V; Calleri A; Mancuso P; Bertolini F
Br J Cancer; 2018 May; 118(10):1329-1336. PubMed ID: 29695766
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral CD8
Virassamy B; Caramia F; Savas P; Sant S; Wang J; Christo SN; Byrne A; Clarke K; Brown E; Teo ZL; von Scheidt B; Freestone D; Gandolfo LC; Weber K; Teply-Szymanski J; Li R; Luen SJ; Denkert C; Loibl S; Lucas O; Swanton C; Speed TP; Darcy PK; Neeson PJ; Mackay LK; Loi S
Cancer Cell; 2023 Mar; 41(3):585-601.e8. PubMed ID: 36827978
[TBL] [Abstract][Full Text] [Related]
15. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
16. LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade.
Liu Y; Debo B; Li M; Shi Z; Sheng W; Shi Y
Nat Commun; 2021 Nov; 12(1):6831. PubMed ID: 34819502
[TBL] [Abstract][Full Text] [Related]
17. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
18. Single-Cell Transcriptome Analysis Reveals the M2 Macrophages and Exhausted T Cells and Intratumoral Heterogeneity in Triple-Negative Breast Cancer.
Xu L; Li C
Anticancer Agents Med Chem; 2022; 22(2):294-312. PubMed ID: 34145996
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
20. Antigen dominance hierarchies shape TCF1
Burger ML; Cruz AM; Crossland GE; Gaglia G; Ritch CC; Blatt SE; Bhutkar A; Canner D; Kienka T; Tavana SZ; Barandiaran AL; Garmilla A; Schenkel JM; Hillman M; de Los Rios Kobara I; Li A; Jaeger AM; Hwang WL; Westcott PMK; Manos MP; Holovatska MM; Hodi FS; Regev A; Santagata S; Jacks T
Cell; 2021 Sep; 184(19):4996-5014.e26. PubMed ID: 34534464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]